Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.42 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.42 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.42 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920846 | 0.84 | MAPK14 (0.47) | LMNARAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL920087 | 0.81 | ALDH1A1 (0.48) | RAB9ASMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL918991 | 0.81 | MAPK14 (0.50) | SMN1; SMN2NPC1MAPTHTTALDH1A1 | |
| SCHEMBL15377800 | 0.80 | MAPK14 (0.42) | LMNASMN1; SMN2HTTKDM4EOPRM1 | |
| SCHEMBL919163 | 0.80 | SCN9A (0.47) | GAA | |
| SCHEMBL919807 | 0.80 | CYP2C19 (0.47) | MEN1KMT2ARAB9ANPC1GAA | |
| SCHEMBL8626757 | 0.77 | OPRM1 (0.48) | OPRM1OPRD1OPRK1P2RX3 | |
| SCHEMBL919293 | 0.76 | SCN9A (0.42) | — | |
| SCHEMBL4377085 | 0.76 | NAMPT (0.52) | MEN1KMT2APLAAT3PLAAT5PLAAT2 | |
| SCHEMBL919046 | 0.75 | MMP13 (0.49) | MEN1KMT2ARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | claimed |
| US-20090240053-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2009-09-24 | — | — | US | claimed |
| US-20060217403-A1 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY | 2006-09-28 | — | — | US | claimed |
| EP-1032377-A4 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2006-06-14 | — | — | EP | claimed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | claimed |
| US-6500825-B2 | SODIUM CHANNEL BLOCKERS USED TO TREAT AMYOTROPHIC LATERAL SCLEROSIS; ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANTS, LOCAL ANESTHETICS AND ANTIARRHYTHMICS | EURO-CELTIQUE S.A. (LU) | 2002-12-31 | — | — | US | claimed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | claimed |
| EP-1032377-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-09-06 | — | — | EP | claimed |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | disclosed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-7872127-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2201944-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-2201945-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | disclosed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240053-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | MEN1 4823/4885KMT2A 889/4885APAF1 1582/4885 |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | MEN1 3675/4885KMT2A 671/4885APAF1 2102/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | MEN1 3719/4885KMT2A 4185/4885APAF1 3924/4885 |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, SLC1A1, SCN2A | MEN1 4844/4885KMT2A 662/4885APAF1 1086/4885 |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | MEN1 4788/4885KMT2A 845/4885APAF1 1466/4885 |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | MEN1 3675/4885KMT2A 671/4885APAF1 2102/4885 |
| US-20060217403-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | MEN1 4823/4885KMT2A 889/4885APAF1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.